- Better Overall CINV Prevention* 1-3
| - |
Acute: ALOXI® 72.0% vs. ondansetron/dolasetron 60.6% |
| - |
Delayed: ALOXI 64% vs. ondansetron/dolasetron 46.8% |
- Only 5-HT3 receptor antagonist indicated for the prevention of delayed CINV associated with moderately emetogenic chemotherapy.4-7
- Highest receptor binding affinity† and longest half-life (~40 hrs) in the class.4-7,8,9
- A single, 0.25 mg fixed IV dose administered over 30 seconds, 30 minutes prior to chemotherapy.4
Click here to review the results of ALOXI Phase III clinical trials.
* Pooled CR rates (no emesis, no rescue medications) from two identically designed phase III clinical trials involving moderately emetogenic chemoterapy: 97.5% CI and two-sided Fisher’s exact test (significance level=0.025) indicate a difference between ALOXI and ondansetron/dolasetron.
†In vitro; clinical significance has not been established.
References
- Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
- Rubenstein EB, Gralla RJ, Eisenberg P, et al. Palonosetron (PALO) compared with Ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase II trials. Proc Am Soc Clin Oncol. 2003;22:729.
- ALOXI® (palonosetron HCl) injection full prescribing information.
- Anzemet® (dolasetron mesylate) full prescribing information.
- Zofran® (ondansetron hydrochloride) full prescribing information.
- Kytril® (granisetron hydrochloride) full prescribing information.
- Wong EHF, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995;114:851-859.